J Cell Physiol:MicroRNA-487a-3p是一个新的前列腺癌肿瘤抑制子

2019-07-31 AlexYang MedSci原创

前列腺癌(PCa)是老年男性的主要健康问题。异常调控的microRNA在PCa中的角色仍旧未知。最近,有研究人员分析了公共数据库并发现,miR-487a-3p在38例前列腺肿瘤样本中明显下调。进一步的组织芯片原位杂交和实时定量数据鉴定了上述发现。研究人员还发现,miR-487a-3p的过表达能够抑制PCa细胞生长、迁移和浸润,具体机制是靶向CCND1。PCa细胞中CCND1的敲除表现出了相似的结果

前列腺癌(PCa)是老年男性的主要健康问题。异常调控的microRNA在PCa中的角色仍旧未知。

最近,有研究人员分析了公共数据库并发现,miR-487a-3p在38例前列腺肿瘤样本中明显下调。进一步的组织芯片原位杂交和实时定量数据鉴定了上述发现。研究人员还发现,miR-487a-3p的过表达能够抑制PCa细胞生长、迁移和浸润,具体机制是靶向CCND1。PCa细胞中CCND1的敲除表现出了相似的结果。同时,CCND1的表达水平在PCa组织和细胞系中明显上调,并与miR-487a-3p表现出了明显的负相关关系。更重要的是,研究人员阐释miR-487a-3p稳定的过表达能够显著的减少异种种植肿瘤的生长。

最后,研究人员指出,他们首次阐释了miR-487a-3p能够通过靶向CCND1来起着PCa抑制子的角色。这也许表明了miR-487a-3p在致病过程中具有作用,并且可以作为新的靶向PCa疗法的临床生物标记。

原始出处:

Wang M, Yu W, Gao J et al. MicroRNA-487a-3p functions as a new tumor suppressor in prostate cancer by targeting CCND1. J Cell Physiol. 15 Jul 2019

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2084542, encodeId=f8b52084542c1, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Mon Apr 20 02:59:00 CST 2020, time=2020-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857820, encodeId=037b185e820d2, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Tue Jul 14 02:59:00 CST 2020, time=2020-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1809159, encodeId=b676180915978, content=<a href='/topic/show?id=a68f829380b' target=_blank style='color:#2F92EE;'>#肿瘤抑制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82938, encryptionId=a68f829380b, topicName=肿瘤抑制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dcaa509, createdName=tsing_hit, createdTime=Tue Oct 01 12:59:00 CST 2019, time=2019-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788927, encodeId=dcf21e8892750, content=<a href='/topic/show?id=866d1421e4c' target=_blank style='color:#2F92EE;'>#Physio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14217, encryptionId=866d1421e4c, topicName=Physio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Mon Jun 29 15:59:00 CST 2020, time=2020-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1871374, encodeId=5df118e1374ea, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Jul 02 12:59:00 CST 2020, time=2020-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1961658, encodeId=ddd51961658e5, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed May 27 08:59:00 CST 2020, time=2020-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1435774, encodeId=bca61435e74ec, content=<a href='/topic/show?id=31df11e1642' target=_blank style='color:#2F92EE;'>#microRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11716, encryptionId=31df11e1642, topicName=microRNA)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Fri Aug 02 03:59:00 CST 2019, time=2019-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040514, encodeId=20f01040514a0, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Jul 31 15:59:00 CST 2019, time=2019-07-31, status=1, ipAttribution=)]
    2020-04-20 xjy02
  2. [GetPortalCommentsPageByObjectIdResponse(id=2084542, encodeId=f8b52084542c1, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Mon Apr 20 02:59:00 CST 2020, time=2020-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857820, encodeId=037b185e820d2, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Tue Jul 14 02:59:00 CST 2020, time=2020-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1809159, encodeId=b676180915978, content=<a href='/topic/show?id=a68f829380b' target=_blank style='color:#2F92EE;'>#肿瘤抑制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82938, encryptionId=a68f829380b, topicName=肿瘤抑制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dcaa509, createdName=tsing_hit, createdTime=Tue Oct 01 12:59:00 CST 2019, time=2019-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788927, encodeId=dcf21e8892750, content=<a href='/topic/show?id=866d1421e4c' target=_blank style='color:#2F92EE;'>#Physio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14217, encryptionId=866d1421e4c, topicName=Physio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Mon Jun 29 15:59:00 CST 2020, time=2020-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1871374, encodeId=5df118e1374ea, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Jul 02 12:59:00 CST 2020, time=2020-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1961658, encodeId=ddd51961658e5, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed May 27 08:59:00 CST 2020, time=2020-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1435774, encodeId=bca61435e74ec, content=<a href='/topic/show?id=31df11e1642' target=_blank style='color:#2F92EE;'>#microRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11716, encryptionId=31df11e1642, topicName=microRNA)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Fri Aug 02 03:59:00 CST 2019, time=2019-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040514, encodeId=20f01040514a0, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Jul 31 15:59:00 CST 2019, time=2019-07-31, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2084542, encodeId=f8b52084542c1, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Mon Apr 20 02:59:00 CST 2020, time=2020-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857820, encodeId=037b185e820d2, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Tue Jul 14 02:59:00 CST 2020, time=2020-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1809159, encodeId=b676180915978, content=<a href='/topic/show?id=a68f829380b' target=_blank style='color:#2F92EE;'>#肿瘤抑制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82938, encryptionId=a68f829380b, topicName=肿瘤抑制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dcaa509, createdName=tsing_hit, createdTime=Tue Oct 01 12:59:00 CST 2019, time=2019-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788927, encodeId=dcf21e8892750, content=<a href='/topic/show?id=866d1421e4c' target=_blank style='color:#2F92EE;'>#Physio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14217, encryptionId=866d1421e4c, topicName=Physio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Mon Jun 29 15:59:00 CST 2020, time=2020-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1871374, encodeId=5df118e1374ea, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Jul 02 12:59:00 CST 2020, time=2020-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1961658, encodeId=ddd51961658e5, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed May 27 08:59:00 CST 2020, time=2020-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1435774, encodeId=bca61435e74ec, content=<a href='/topic/show?id=31df11e1642' target=_blank style='color:#2F92EE;'>#microRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11716, encryptionId=31df11e1642, topicName=microRNA)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Fri Aug 02 03:59:00 CST 2019, time=2019-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040514, encodeId=20f01040514a0, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Jul 31 15:59:00 CST 2019, time=2019-07-31, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2084542, encodeId=f8b52084542c1, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Mon Apr 20 02:59:00 CST 2020, time=2020-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857820, encodeId=037b185e820d2, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Tue Jul 14 02:59:00 CST 2020, time=2020-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1809159, encodeId=b676180915978, content=<a href='/topic/show?id=a68f829380b' target=_blank style='color:#2F92EE;'>#肿瘤抑制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82938, encryptionId=a68f829380b, topicName=肿瘤抑制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dcaa509, createdName=tsing_hit, createdTime=Tue Oct 01 12:59:00 CST 2019, time=2019-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788927, encodeId=dcf21e8892750, content=<a href='/topic/show?id=866d1421e4c' target=_blank style='color:#2F92EE;'>#Physio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14217, encryptionId=866d1421e4c, topicName=Physio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Mon Jun 29 15:59:00 CST 2020, time=2020-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1871374, encodeId=5df118e1374ea, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Jul 02 12:59:00 CST 2020, time=2020-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1961658, encodeId=ddd51961658e5, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed May 27 08:59:00 CST 2020, time=2020-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1435774, encodeId=bca61435e74ec, content=<a href='/topic/show?id=31df11e1642' target=_blank style='color:#2F92EE;'>#microRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11716, encryptionId=31df11e1642, topicName=microRNA)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Fri Aug 02 03:59:00 CST 2019, time=2019-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040514, encodeId=20f01040514a0, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Jul 31 15:59:00 CST 2019, time=2019-07-31, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2084542, encodeId=f8b52084542c1, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Mon Apr 20 02:59:00 CST 2020, time=2020-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857820, encodeId=037b185e820d2, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Tue Jul 14 02:59:00 CST 2020, time=2020-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1809159, encodeId=b676180915978, content=<a href='/topic/show?id=a68f829380b' target=_blank style='color:#2F92EE;'>#肿瘤抑制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82938, encryptionId=a68f829380b, topicName=肿瘤抑制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dcaa509, createdName=tsing_hit, createdTime=Tue Oct 01 12:59:00 CST 2019, time=2019-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788927, encodeId=dcf21e8892750, content=<a href='/topic/show?id=866d1421e4c' target=_blank style='color:#2F92EE;'>#Physio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14217, encryptionId=866d1421e4c, topicName=Physio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Mon Jun 29 15:59:00 CST 2020, time=2020-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1871374, encodeId=5df118e1374ea, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Jul 02 12:59:00 CST 2020, time=2020-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1961658, encodeId=ddd51961658e5, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed May 27 08:59:00 CST 2020, time=2020-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1435774, encodeId=bca61435e74ec, content=<a href='/topic/show?id=31df11e1642' target=_blank style='color:#2F92EE;'>#microRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11716, encryptionId=31df11e1642, topicName=microRNA)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Fri Aug 02 03:59:00 CST 2019, time=2019-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040514, encodeId=20f01040514a0, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Jul 31 15:59:00 CST 2019, time=2019-07-31, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2084542, encodeId=f8b52084542c1, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Mon Apr 20 02:59:00 CST 2020, time=2020-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857820, encodeId=037b185e820d2, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Tue Jul 14 02:59:00 CST 2020, time=2020-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1809159, encodeId=b676180915978, content=<a href='/topic/show?id=a68f829380b' target=_blank style='color:#2F92EE;'>#肿瘤抑制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82938, encryptionId=a68f829380b, topicName=肿瘤抑制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dcaa509, createdName=tsing_hit, createdTime=Tue Oct 01 12:59:00 CST 2019, time=2019-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788927, encodeId=dcf21e8892750, content=<a href='/topic/show?id=866d1421e4c' target=_blank style='color:#2F92EE;'>#Physio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14217, encryptionId=866d1421e4c, topicName=Physio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Mon Jun 29 15:59:00 CST 2020, time=2020-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1871374, encodeId=5df118e1374ea, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Jul 02 12:59:00 CST 2020, time=2020-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1961658, encodeId=ddd51961658e5, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed May 27 08:59:00 CST 2020, time=2020-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1435774, encodeId=bca61435e74ec, content=<a href='/topic/show?id=31df11e1642' target=_blank style='color:#2F92EE;'>#microRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11716, encryptionId=31df11e1642, topicName=microRNA)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Fri Aug 02 03:59:00 CST 2019, time=2019-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040514, encodeId=20f01040514a0, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Jul 31 15:59:00 CST 2019, time=2019-07-31, status=1, ipAttribution=)]
    2020-05-27 维他命
  7. [GetPortalCommentsPageByObjectIdResponse(id=2084542, encodeId=f8b52084542c1, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Mon Apr 20 02:59:00 CST 2020, time=2020-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857820, encodeId=037b185e820d2, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Tue Jul 14 02:59:00 CST 2020, time=2020-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1809159, encodeId=b676180915978, content=<a href='/topic/show?id=a68f829380b' target=_blank style='color:#2F92EE;'>#肿瘤抑制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82938, encryptionId=a68f829380b, topicName=肿瘤抑制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dcaa509, createdName=tsing_hit, createdTime=Tue Oct 01 12:59:00 CST 2019, time=2019-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788927, encodeId=dcf21e8892750, content=<a href='/topic/show?id=866d1421e4c' target=_blank style='color:#2F92EE;'>#Physio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14217, encryptionId=866d1421e4c, topicName=Physio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Mon Jun 29 15:59:00 CST 2020, time=2020-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1871374, encodeId=5df118e1374ea, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Jul 02 12:59:00 CST 2020, time=2020-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1961658, encodeId=ddd51961658e5, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed May 27 08:59:00 CST 2020, time=2020-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1435774, encodeId=bca61435e74ec, content=<a href='/topic/show?id=31df11e1642' target=_blank style='color:#2F92EE;'>#microRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11716, encryptionId=31df11e1642, topicName=microRNA)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Fri Aug 02 03:59:00 CST 2019, time=2019-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040514, encodeId=20f01040514a0, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Jul 31 15:59:00 CST 2019, time=2019-07-31, status=1, ipAttribution=)]
    2019-08-02 zhouqu_8
  8. [GetPortalCommentsPageByObjectIdResponse(id=2084542, encodeId=f8b52084542c1, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Mon Apr 20 02:59:00 CST 2020, time=2020-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857820, encodeId=037b185e820d2, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Tue Jul 14 02:59:00 CST 2020, time=2020-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1809159, encodeId=b676180915978, content=<a href='/topic/show?id=a68f829380b' target=_blank style='color:#2F92EE;'>#肿瘤抑制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82938, encryptionId=a68f829380b, topicName=肿瘤抑制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dcaa509, createdName=tsing_hit, createdTime=Tue Oct 01 12:59:00 CST 2019, time=2019-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788927, encodeId=dcf21e8892750, content=<a href='/topic/show?id=866d1421e4c' target=_blank style='color:#2F92EE;'>#Physio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14217, encryptionId=866d1421e4c, topicName=Physio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Mon Jun 29 15:59:00 CST 2020, time=2020-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1871374, encodeId=5df118e1374ea, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Jul 02 12:59:00 CST 2020, time=2020-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1961658, encodeId=ddd51961658e5, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed May 27 08:59:00 CST 2020, time=2020-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1435774, encodeId=bca61435e74ec, content=<a href='/topic/show?id=31df11e1642' target=_blank style='color:#2F92EE;'>#microRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11716, encryptionId=31df11e1642, topicName=microRNA)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Fri Aug 02 03:59:00 CST 2019, time=2019-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040514, encodeId=20f01040514a0, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Jul 31 15:59:00 CST 2019, time=2019-07-31, status=1, ipAttribution=)]
    2019-07-31 misszhang

    前列腺癌相关研究,学习了,谢谢梅斯

    0

相关资讯

Mol Med Rep:MicroRNA 663能够抑制透明细胞肾细胞癌细胞的增殖和入侵

越来越多的证据阐释了microRNAs(miRNAs)在透明细胞肾细胞癌(ccRCC)中是关键的基因调控子并且表达异常。miRNAs表达的异常在ccRCC的起始和恶化过程中具有作用。因此,对ccRCC相关miRNAs的鉴定能够促使抗癌治疗有效治疗靶标的确定。最近,有研究人员发现在ccRCC组织和细胞系中,miRNA-663(miR-663)的表达下调。功能鉴定试验表明了miR-663表达的恢复能够

Eur Rev Med Pharmacol Sci:在前列腺癌细胞中,miR-195对MAP2K1的靶向调控能够抑制ADM药物抗性

细胞外信号调控的激酶/线粒体激活蛋白激酶(ERK/MAPK)信号途径参与了细胞增殖、周期和凋亡。MAPK激酶1(MAP2K1)能够激活ERK/MAPK途径。miR-195的下调与前列腺癌起始和药物抗性相关。生物信息学分析鉴定了miR-195与MAP2K1之间存在互补结合位点。最近,有研究人员调查了miR-195对前列腺癌细胞增殖、凋亡和亚得里亚霉素(ADM)抗性的影响。研究发现,miR-195与M

Cell:利用小RNA制造完美的卵子

所有有性繁殖的多细胞生物依赖于卵子支撑早期生命。在一项新的研究中,来自美国加州大学圣地亚哥分校医学院和路德维格癌症研究所(Ludwig Institute for Cancer Research)的研究人员利用细小的秀丽隐杆线虫(Caenorhabditis elegans)作为模式生物开展研究以便更好地理解卵子如何能够发育成胚胎。他们揭示出小RNA和辅助蛋白在微调卵子发育中发挥着作用。相关

Sci Rep:miRNA-302s可能是人类睾丸生殖细胞瘤的致瘤基因

在世界大部分范围内,睾丸生殖细胞瘤(TGCT)是年轻男性最常见的恶性肿瘤,但是其中的病因学仍旧未知。研究人员已经鉴定了多个TGCT易感位点,并且已经阐释了SPRY4可能是TGCT的一个致瘤基因。更多的是,其中的许多位点为基因组的非编码区域。miRNA在TGCT和正常睾丸中的差异表达之前已有报道。最近,有研究人员使用qPCR的方法来分析正常和恶性睾丸组织中,10个miRNA的表达情况,这10个miR

Eur Rev Med Pharmacol Sci:miR-487b能够通过对IL-33/ST2信号途径的抑制减轻过敏性鼻炎

最近,有研究人员调查了miR-487b/IL-33-ST2途径对过敏性鼻炎(AR)病理的潜在影响和相关的机制。研究人员在患有和不患有过敏性鼻炎的患者中检测了IL-33、磺基转移酶同系物(ST2)和miR-487b的表达水平,并利用荧光素酶报告试验评估了miR-487b与IL-33之间的互作。研究人员还利用小鼠模型来探究miR-487b/IL-33-ST2途径对过敏性鼻炎的影响。研究发现,IL-33